Objective: Having demonstrated short-term weight loss with liraglutide in this group of obese
adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for …

Aim: The effect on body composition of liraglutide, a once‐daily human glucagon‐like
peptide‐1 analogue, as monotherapy or added to metformin was examined in patients with …

Aim To confirm the superiority, compared with placebo, of adding liraglutide to pre‐existing
basal insulin analogue±metformin in adults with inadequately controlled type 2 diabetes …

Objective To assess the efficacy and safety of adding liraglutide to established insulin
therapy in poorly controlled Chinese subjects with type 2 diabetes and abdominal obesity …

Aim: The aim of this study was to compare the efficacy and safety of once‐daily human
glucagon‐like peptide‐1 analogue liraglutide with dipeptidyl peptidase‐4 inhibitor …

Aim: Effective type 2 diabetes management requires a multifactorial approach extending
beyond glycaemic control. Clinical practice guidelines suggest targets for HbA1c, blood …

OBJECTIVE—Glucagon-like peptide (GLP)-1 is a gut hormone that exerts incretin effects
and suppresses food intake in humans, but its therapeutic use is limited due to its short half …

Aims Liraglutide (NN2211) is a long‐acting GLP‐1 analogue, with a pharmacokinetic profile
suitable for once‐daily administration. This multicentre, double‐blind, parallel‐group, double …

Aims To investigate efficacy and safety of dual therapy with liraglutide and metformin in
comparison to glimepiride and metformin, and metformin monotherapy over 2 years in …

Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone
4 mg/day (all n≥ 228) or placebo (n= 114) with glimepiride (2–4 mg/day) on glycaemic …